Procter & Gamble Drops Out Of Somaxon's OTC Silenor Effort
The two companies agreed in November to evaluate the potential to develop and commercialize the doxepin-based product. Their agreement included jointly developing a desired product profile and conducting market research at P&G’s expense, according to a November U.S. Securities and Exchange Commission filing from Somaxon.
With P&G opting out of the...
To view the full article, register now.